Summary
A physician aged 44 years participated as a volunteer in pharmacokinetic studies with tinidazole (FASIGYN, Pfizer). He received 1600 mg of the drug as an intravenous infusion over 80 min. Shortly afterwards, he fainted and was unconscious for about 10 s. The attack was followed by low blood pressure, nausea and tiredness for several h. The serum concentration of tinidazole was 35.4 mg/l when the attack started. Blood tests showed a normal immunoglobulin E level, and a transient fall in the concentration of complement factor C3 after the infusion. It is concluded that tinidazole caused an acute toxic reaction with subsequent activation of complement factors.
References
Bergan T, Aase S, Leinebø O, Roland M, Harbitz T, Olsen AK, Liavåg I (1983) Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose. Acta Pathol Microbiol Scand [Suppl]: (in press)
Salvesen B, Leinebø O, Bergan T (1983) Assay of metronidazole by HPLC compared to a microbiological method. Acta Pathol Microbiol Scand [Suppl]: (in press)
Schärer K (1972) Selective alterations of Purkinje cells in the dog after oral administration of high doses of nitroimidazole derivatives. Verh Dtsch Ges Pathol 56: 407–410
Harris JW, Shrieve DC (1978) Misonidazole (Ro-07-0582) sensitizes mice to convulsions induced by hyperbaric oxygen or pentylenetetrazol. Br J Radiol 51: 1024–1025
Frytak S, Moertel CG, Childs DS, Albers JW (1978) Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88: 361–362
Thomas GM, Rauth AM, Bush RS, Black BE, Cummings BJ (1980) A toxicity study of daily dose metronidazole with pelvic irradiation. Cancer Clin Trials 3: 223–230
Austen KF (1979) The classical and alternative complement sequence. In: Benacerraf B, Unanue ER (eds) Textbook of immunology. Williams and Wilkins, Baltimore, pp 218–238
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aase, S., Olsen, A.K., Roland, M. et al. Severe toxic reaction to tinidazole. Eur J Clin Pharmacol 24, 425–427 (1983). https://doi.org/10.1007/BF00610066
Issue Date:
DOI: https://doi.org/10.1007/BF00610066